EE692 Cost-Effectiveness of Nivolumab (NIVO) and NIVO in Combination With Ipilimumab (IPI) in First-Line Treatment of Advanced Melanoma in Colombia: Analysis Using 78-Month Overall Survival From CheckMate 067
Abstract
Authors
R. Kendall V. Barco A. Sharma L. McDonald J. Garcia Perlaza T. Baker